Multiple targets, highly effective, breakthrough therapy for ALS sufferers may now be within reach. Winston Ko, the CEO of Genervon Biopharmaceuticals, will be presenting on Friday at the Neurotech Conference in San Francisco that its endogenous regulatory drug GM604 modulates over 80 ALS related gene targets interactively and dynamically through 12 pathways and up to 22 biological processes, including neurogenesis, neural development, signaling and transport...
European Patent Office Issues Its Intention to Grant Genervon Biopharmaceuticals a European Patent on Methods of Treating Neuronal Disorders Using MNTF Peptides and Analogs Thereof
The European Patent Office notified Genervon of its intention to grant a European patent on Methods of Treating Neuronal Disorders using MNTF peptides and analogs thereof. Genervon will proceed to have the patents for EPO application No. 07867451.2 issued, bringing the portfolio of Genervon's issued Composition of Matters and Use patents to 46...